Zhang Boli: research and development of new drugs in line with Chinese industrial characteristics

Zhang Boli, academician of Chinese Academy of engineering and President of Tianjin University of traditional Chinese medicine, made a keynote speech entitled "progress and trend of new drug research and development in China", the scene of the 26th national pharmaceutical economic information conference In the report on meeting the challenges of the 21st century, who pointed out that "medicine in the 21st century should not continue to focus on diseases, but on human health." Health is the basic right of human beings, and the purpose of medicine is to discover and develop human self-health ability Innovation highlights Chinese characteristics as a major country accounting for 22% of the world's total population In 2011, China has surpassed Japan as the second largest pharmaceutical industry country, and it is expected to reach or exceed the scale of the United States by 2020 However, although the volume and scale of China's pharmaceutical industry are increasing year by year, the total output value only accounts for 7% of the world's total, and drug R & D is still dominated by imitation, which is difficult to withstand the strong impact of international competition In this context, the State Council approved "major new drug creation" as one of the 16 major national science and technology projects in 2005, aiming to improve the core competitiveness of China's pharmaceutical industry by supporting and encouraging the research and development of innovative drugs, technological transformation of large varieties of drugs, construction of innovative drug research technology platform, construction of enterprise new drug incubation base and Research on Key Technologies of new drug research and development As the Deputy Chief Technology Engineer of the major project, academician Zhang Boli made a specific review on the breakthrough of key technologies in new drug research and development, as well as the construction of a first-class platform, and the research of more new drugs in line with international standards According to reports, since the start of the project, as of September 2013, a total of 52 varieties have obtained 74 new drug certificates, including 10 new drug certificates of traditional Chinese medicine At the same time, it has broken through a series of key technologies of new drug research and development and built a high-level research platform Through the support of this major project, enterprises are encouraged to actively cooperate with scientific research institutes During the 12th Five Year Plan period, the strength of Chinese pharmaceutical enterprises has significantly increased The number of enterprises with sales exceeding 10 billion yuan and 5 billion yuan has greatly increased The overall output value scale has maintained a growth of 21% It is estimated that the total output value of the pharmaceutical industry will exceed 3 trillion yuan in 2015 "Strategically, China's new drug R & D positioning should be combined with the actual situation of its own industry Chemical drugs should narrow the gap with the advanced level of foreign countries Biological drugs should keep pace with the development of foreign countries and make a stable layout, while traditional Chinese medicine should lead the world." Under the condition of limited resources, we should pay attention to the secondary development of traditional Chinese medicine to meet the medical needs of 1.3 billion people The data shows that the proportion of TCM institutions in the national health institutions is 4.5%, the proportion of TCM personnel in the national health personnel is 7.5%, and the proportion of financial allocation of TCM institutions in the health allocation is 6.56% However, the number of TCM outpatient services accounts for 15% of the national outpatient services, and the number of TCM discharged patients accounts for 12% of the total discharged patients "These data are a powerful proof of the advantages of" simplicity, convenience, honesty and efficacy "of traditional Chinese medicine If we break through the shackles of" tonifying medicine with medicine ", the advantages of traditional Chinese medicine will become more prominent." Multinational pharmaceutical enterprises have also seen the market opportunities in the field of traditional Chinese medicine in China, and frequently involved in the big health market of traditional Chinese medicine through capital means, such as Bayer's purchase of Yunnan Dianhong with 3.6 billion yuan, GSK, Pfizer, Sanofi and other enterprises are also entering the field of traditional Chinese medicine Zhang Boli thought: "if the domestic market of traditional Chinese medicine wants to be bigger, it is necessary to see the characteristics of traditional Chinese medicine clearly It is necessary to combine modern scientific and technological achievements, strengthen basic research and clinical research, use evidence-based medical evidence to prove the clinical safety and clinical efficacy of traditional Chinese medicine, strengthen pharmaceutical technology research, optimize technology, and improve the consistency and quality between different batches of traditional Chinese medicine Including raw material planting, quality control, preparation technology, safety evaluation, clinical re evaluation and other aspects must be systematically studied In particular, we should pay attention to the study of traditional classical prescriptions and drugs, conduct in-depth study on drugs with definite curative effect, clarify clinical positioning, reveal its scientific connotation, and carry out secondary development " The second development strategy of large varieties of traditional Chinese medicine has made outstanding achievements The secondary development of 32 varieties of Chinese patent medicines led by Zhang Boli increased from 3 to 12 varieties with a sales volume of more than 100 million yuan In 2013, the sales volume exceeded 5 billion yuan, an increase of 4.2 times, and the cumulative sales volume reached 20 billion yuan The secondary development mode of famous and excellent Chinese patent medicines was established, which made progress in the secondary development of Chinese patent medicines in dozens of leading Chinese traditional medicine enterprises in China, and also promoted the health of large and medium-sized medicines Health industry development "We should seize the major opportunity of a new round of scientific and technological revolution and industrial transformation, join in the construction of new venues at the beginning, and even become an important maker of new competition rules and a leader in the construction of new venues; traditional Chinese medicine should bear the requirements of the times and historical responsibility, and lead and lead the research and development of global traditional Chinese medicine and natural medicine on its own strength."